paints a grim picture of TransMedics' business practices. The report's allegations center on the company's warm perfusion technology platform, known as the Organ Care System (OCS), and its ...

paints a grim picture of TransMedics’ business practices. The report’s allegations center on the company’s warm perfusion technology platform, known as the Organ Care System (OCS), and its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NCC AB Series B rounded out the top three leaders on Wednesday, with shares gaining 6.2%. Xvivo Perfusion AB posted the largest decline, dropping 7.2%, followed by Oersted A/S shares, which ...

We've identified the following companies as similar to Xvivo Perfusion AB (publ) because they operate in a related industry or sector. We also considered size, growth, and various financial ...

HB Wealth Management LLC lifted its holdings in shares of TransMedics Group ... The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that ...

LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ...

clinical resources and next-generation Organ Care System (OCS) technologies. TransMedics now expects revenues for the full year to be in the range of $428 million-$432 million (representing growth ...